Netrin-3 attenuates metabolic dysfunction-associated fatty liver disease by activating the AMPK-PPARα axis
BACKGROUND: Metabolic dysfunction-associated fatty liver disease (MAFLD) is characterized by hepatic steatosis and can progress to steatohepatitis. Netrin-3, an axon guidance protein linked to metabolic homeostasis, has not been characterized in MAFLD. METHODS: MAFLD was induced in mice by high-fat diet. Netrin-3 and UNC5A expression was measured in serum and liver. Recombinant Netrin-3 was administered with or without Compound C. Hepatic AMPK/ACC phosphorylation, PPARα and target genes, lipid and glucose profiles, insulin, and liver injury were assessed. AML12 hepatocytes with fatty acid overload were treated with Netrin-3, Compound C, or AMPKα siRNA. RESULTS: Netrin-3 and UNC5A were downregulated in MAFLD mice. Netrin-3 treatment reduced body weight, adiposity, dyslipidemia, hyperglycemia, hyperinsulinemia, ALT/AST levels, and hepatic steatosis. It increased AMPK and ACC phosphorylation and restored PPARα, Fabp1, and CPT1α expression. Compound C reversed these protective effects in vivo. In AML12 cells, Netrin-3 activated AMPK/ACC signaling, and this effect was abolished by Compound C and AMPKα siRNA. CONCLUSIONS: Netrin-3 attenuates MAFLD progression by activating the hepatic AMPK-PPARα axis and promoting fatty acid oxidation, identifying Netrin-3 as a candidate therapeutic molecule for fatty liver disease.
Authors
- Feng Dong
- Zhenfei Hong
Institutions
- Shanghai Ship and Shipping Research Institute (CN)
Publication Details
- Journal
- Archives of Physiology and Biochemistry
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1080/13813455.2026.2752268
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00